Neurocrine Biosciences Unveils Expanded R&D Strategy, Advances Phase 3 Neuropsychiatry Pipeline And CRF Platform For Metabolic Diseases

Provided Update on R&D Engine Now On Track to Deliver Multiple First- and Best-in-Class Medicines, Positioning Company for Long-Term Value Creation Across Therapeutic Modalities

Reviewed Positive Data Across Late-Stage Neuropsychiatry Pipeline Including Osavampator and Direclidine; Topline Phase 3 Data from Both Programs Expected in 2027

Announced Expansion of CRF Platform as Foundation of New Class of Medicines for Metabolic Diseases, Including Obesity

SAN DIEGO, Dec. 16, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced a new chapter in its research and development strategy, designed to fuel the Company's next era for growth and deliver long-term value. Neurocrine highlighted this business strategy during its 2025 R&D Day at its headquarters in San Diego, CA.

Building on three decades of leadership in neurology, psychiatry, and endocrinology, Neurocrine is advancing a diversified pipeline of first- and best-in-class medicines across therapeutic modalities including two Phase 3 programs, osavampator for major depressive disorder and direclidine for schizophrenia. The company's clinical portfolio includes a rich pipeline of early- to mid-stage muscarinic agonists and VMAT2 inhibitors for the treatment of neuropsychiatric indications, and CRF-based therapies for metabolic diseases, including obesity. By the end of the decade, Neurocrine expects its R&D engine to deliver an approved medicine every two years.